Latest / Decera Clinical Education Oncology Podcast
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions
In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:
Genomic testing options for assessing risk of recurrence
Adjuvant treatment duration and holidays with CDK4/6 inhibitors
Managing renal toxicities, prophylaxis for DVT, and asymptomatic ILD
CDK4/6 inhibitors with inavolisib and fulvestrant
Presenters:
William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.